{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Allergen&page=5",
    "query": {
      "intervention": "Allergen",
      "page": 5
    },
    "page_size": 10
  },
  "pagination": {
    "page": 5,
    "page_size": 10,
    "total_count": 226,
    "total_pages": 23,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Allergen&page=6&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Allergen&page=4&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-20T17:01:22.956Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02237196",
      "title": "Anti-TSLP (AMG 157) Plus Antigen-Specific Immunotherapy for Induction of Tolerance in Individuals With Cat Allergy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Cat Allergy",
        "Cat Hypersensitivity"
      ],
      "interventions": [
        {
          "name": "AMG 157",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Cat Immunotherapy",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Cat Immunotherapy Placebo",
          "type": "BIOLOGICAL"
        },
        {
          "name": "AMG 157 Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 121,
      "start_date": "2015-03-03",
      "completion_date": "2019-03-04",
      "has_results": true,
      "last_update_posted_date": "2020-05-06",
      "last_synced_at": "2026-10-20T17:01:22.956Z",
      "location_count": 9,
      "location_summary": "Los Angeles, California • Denver, Colorado • Chicago, Illinois + 5 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02237196"
    },
    {
      "nct_id": "NCT02601690",
      "title": "Observational Analysis of T Cell Responses to SPIREs for Multiple Allergens in Subjects With Allergy in North America",
      "overall_status": "TERMINATED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Allergy"
      ],
      "interventions": [
        {
          "name": "Blood Sampling",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Adiga Life Sciences, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 199,
      "start_date": "2015-10",
      "completion_date": "2017-06-25",
      "has_results": false,
      "last_update_posted_date": "2019-04-09",
      "last_synced_at": "2026-10-20T17:01:22.956Z",
      "location_count": 2,
      "location_summary": "Upland, California • Fairfax, Virginia",
      "locations": [
        {
          "city": "Upland",
          "state": "California"
        },
        {
          "city": "Fairfax",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02601690"
    },
    {
      "nct_id": "NCT01904604",
      "title": "Peanut Epicutaneous Phase II Immunotherapy Clinical Trial",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Peanut Hypersensitivity",
        "Food Hypersensitivity",
        "Hypersensitivity",
        "Hypersensitivity, Immediate"
      ],
      "interventions": [
        {
          "name": "Placebo Viaskin® Patch",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Low-dose DBV712 Viaskin® Patch",
          "type": "BIOLOGICAL"
        },
        {
          "name": "High-dose DBV712 Viaskin® Patch",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "4 Years",
        "maximum_age": "25 Years",
        "sex": "ALL",
        "summary": "4 Years to 25 Years"
      },
      "enrollment_count": 75,
      "start_date": "2013-09",
      "completion_date": "2018-08-21",
      "has_results": true,
      "last_update_posted_date": "2019-07-01",
      "last_synced_at": "2026-10-20T17:01:22.956Z",
      "location_count": 5,
      "location_summary": "Little Rock, Arkansas • Denver, Colorado • Baltimore, Maryland + 2 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01904604"
    },
    {
      "nct_id": "NCT00640614",
      "title": "Clinical Evaluation of T.R.U.E. TEST® : Safety and Efficacy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Contact Dermatitis"
      ],
      "interventions": [
        {
          "name": "T.R.U.E. TEST® Skin Patch Test: Dose Response Allergens",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Allerderm",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 235,
      "start_date": "2008-04",
      "completion_date": "2009-10",
      "has_results": true,
      "last_update_posted_date": "2020-05-05",
      "last_synced_at": "2026-10-20T17:01:22.956Z",
      "location_count": 4,
      "location_summary": "Little Rock, Arkansas • Shawnee Mission, Kansas • Louisville, Kentucky + 1 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Shawnee Mission",
          "state": "Kansas"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        },
        {
          "city": "Mineola",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00640614"
    },
    {
      "nct_id": "NCT03736447",
      "title": "Peanut Oral Immunotherapy Study of Early Intervention for Desensitization",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Peanut Allergy"
      ],
      "interventions": [
        {
          "name": "AR101 powder provided in capsules & sachets",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo powder provided in capsules & sachets",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Aimmune Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "3 Years",
        "sex": "ALL",
        "summary": "1 Year to 3 Years"
      },
      "enrollment_count": 146,
      "start_date": "2018-12-27",
      "completion_date": "2022-07-05",
      "has_results": true,
      "last_update_posted_date": "2023-03-02",
      "last_synced_at": "2026-10-20T17:01:22.956Z",
      "location_count": 14,
      "location_summary": "Little Rock, Arkansas • Mountain View, California • Rolling Hills Estates, California + 11 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Mountain View",
          "state": "California"
        },
        {
          "city": "Rolling Hills Estates",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03736447"
    },
    {
      "nct_id": "NCT02978183",
      "title": "Evaluation of the Effectiveness of ST266 Ophthalmic Drops Compared to Placebo to Treat Allergic Conjunctivitis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Allergic Conjunctivitis"
      ],
      "interventions": [
        {
          "name": "ST266",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Saline (0.9% NaCl)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Noveome Biotherapeutics, formerly Stemnion",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 70,
      "start_date": "2016-12",
      "completion_date": "2017-11",
      "has_results": true,
      "last_update_posted_date": "2023-04-10",
      "last_synced_at": "2026-10-20T17:01:22.956Z",
      "location_count": 2,
      "location_summary": "Andover, Massachusetts • Memphis, Tennessee",
      "locations": [
        {
          "city": "Andover",
          "state": "Massachusetts"
        },
        {
          "city": "Memphis",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02978183"
    },
    {
      "nct_id": "NCT03887026",
      "title": "Efficacy and Safety of Norketotifen in Adults With Allergic Rhinitis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Allergic Rhinitis",
        "Allergic Rhinoconjunctivitis"
      ],
      "interventions": [
        {
          "name": "Norketotifen",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Emergo Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 36,
      "start_date": "2019-04-01",
      "completion_date": "2019-05-29",
      "has_results": false,
      "last_update_posted_date": "2020-08-21",
      "last_synced_at": "2026-10-20T17:01:22.956Z",
      "location_count": 1,
      "location_summary": "San Antonio, Texas",
      "locations": [
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03887026"
    },
    {
      "nct_id": "NCT00836485",
      "title": "Evaluation of the Safety and Efficacy of Ketotifen 4.0% Patch as Compared to Placebo Patch, Olopatadine 0.2% Ophthalmic Solution, and Artificial Tears in the Conjunctival Allergen Challenge (CAC) Model of Acute Allergic Conjunctivitis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Allergic Conjunctivitis"
      ],
      "interventions": [
        {
          "name": "Ketotifen 4.0% Patch",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Olopatadine 0.2%",
          "type": "DRUG"
        },
        {
          "name": "Artificial tears",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Senju USA, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 122,
      "start_date": "2009-02",
      "completion_date": "2009-03",
      "has_results": false,
      "last_update_posted_date": "2023-08-04",
      "last_synced_at": "2026-10-20T17:01:22.956Z",
      "location_count": 1,
      "location_summary": "Andover, Massachusetts",
      "locations": [
        {
          "city": "Andover",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00836485"
    },
    {
      "nct_id": "NCT01987817",
      "title": "Oral Desensitization to Peanut in Peanut-Allergic Children and Adults Using Characterized Peanut Allergen OIT",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Peanut Allergy"
      ],
      "interventions": [
        {
          "name": "AR101 powder provided in capsules",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo powder provided in capsules",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Aimmune Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "4 Years",
        "maximum_age": "26 Years",
        "sex": "ALL",
        "summary": "4 Years to 26 Years"
      },
      "enrollment_count": 56,
      "start_date": "2014-02-06",
      "completion_date": "2015-01-07",
      "has_results": true,
      "last_update_posted_date": "2021-11-30",
      "last_synced_at": "2026-10-20T17:01:22.956Z",
      "location_count": 8,
      "location_summary": "Little Rock, Arkansas • San Diego, California • Boston, Massachusetts + 5 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01987817"
    },
    {
      "nct_id": "NCT00640250",
      "title": "Clinical Evaluation of T.R.U.E. TEST® Panel 3.2 Allergens: Dose Response",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Contact Dermatitis"
      ],
      "interventions": [
        {
          "name": "T.R.U.E. TEST® Skin Patch Test: Dose Response Allergens",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Allerderm",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 48,
      "start_date": "2008-04",
      "completion_date": "2009-09",
      "has_results": true,
      "last_update_posted_date": "2018-04-09",
      "last_synced_at": "2026-10-20T17:01:22.956Z",
      "location_count": 1,
      "location_summary": "Louisville, Kentucky",
      "locations": [
        {
          "city": "Louisville",
          "state": "Kentucky"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00640250"
    }
  ]
}